LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Takeda Pharmaceutical Co Ltd ADR

Fermé

SecteurSoins de santé

14.1 0.79

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.96

Max

14.1

Chiffres clés

By Trading Economics

Revenu

-68B

24B

Ventes

-32B

1.1T

P/E

Moyenne du Secteur

31.533

56.602

BPA

0.048

Rendement du dividende

4.33

Marge bénéficiaire

2.08

EBITDA

-4.3B

380B

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.33%

2.45%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

45B

Ouverture précédente

13.31

Clôture précédente

14.1

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 mai 2025, 08:08 UTC

Résultats

Takeda's Annual Net Profit Slumps on Expenses, Costs

9 avr. 2025, 09:39 UTC

Principaux Mouvements du Marché

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30 janv. 2025, 11:02 UTC

Résultats

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

30 janv. 2025, 07:53 UTC

Résultats

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

8 mai 2025, 06:34 UTC

Résultats

Takeda Pharmaceutical FY Net Profit Missed Y134.71B Expected in Poll of Analysts by Quick >4502.TO

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical FY EPS Y68.36 Vs EPS Y92.09

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical FY Net Y107.93B Vs Net Y144.07B

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical Sees FY Net Y228.00B

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical FY Oper Pft Y342.59B Vs Pft Y214.08B

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical FY Rev Y4.58T Vs Y4.26T

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical Raises FY Dividend to Y196.00

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical FY Pretax Pft Y175.08B Vs Pft Y52.79B

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical FY Net Y107.93B Vs Net Y144.07B

8 mai 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical Sees FY Net Y228.00B

30 janv. 2025, 07:12 UTC

Résultats

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

30 janv. 2025, 07:08 UTC

Résultats

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

30 janv. 2025, 06:42 UTC

Résultats

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

30 janv. 2025, 06:40 UTC

Résultats

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

30 janv. 2025, 06:36 UTC

Résultats

Takeda: to Discontinue Soticlestat Development Program

30 janv. 2025, 06:34 UTC

Résultats

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

30 janv. 2025, 06:32 UTC

Résultats

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

30 janv. 2025, 06:31 UTC

Résultats

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical Sees FY Net Y118.00B

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical Sees FY Net Y118.00B

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical Raises FY Dividend to Y196.00

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

30 janv. 2025, 06:30 UTC

Résultats

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

Comparaison

Variation de prix

Takeda Pharmaceutical Co Ltd ADR prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 15.16Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.